Physician profile
Angela Wang
NPI 1730133976
$12,487.24
in general payments reported to CMS, 2019-2025
14 companies · $13.72 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $11K · 2022: $23.05 · 2023: $215 · 2024: $130 · 2025: $13.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,241.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.27 | 2019-2024 | Ofev |
| Ge Healthcare | $284.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $227.02 | 2019-2024 | Tezspire |
| Genzyme Corporation | $105.05 | 2019-2024 | |
| Philips North America LLC | $73.22 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $56.52 | 2019 | |
| Insmed, INC. | $41.52 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $31.03 | 2019 | |
| Pfizer INC. | $26.24 | 2019 | |
| Mylan Specialty L.P. | $21.46 | 2019 | |
| United Therapeutics Corporation | $21.40 | 2019 | |
| Incyte Corporation | $13.72 | 2025 | Zynyz, Monjuvi |
| Shire North American Group INC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.